Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pathogenesis(pgns) -- Ignore unavailable to you. Want to Upgrade?

To: Bob Eskimo who wrote (143)	3/22/1999 5:11:00 PM
From: Howard Clark	Read Replies (3) \| Respond to of 228

Double ouch. This is gonna hurt. Based on current sales levels and patient demand indicators, first quarter sales of TOBI are expected to be about $10 million. As a result, the company expects to report a net loss of about $4.9 million or 30 cents per share in the first quarter, versus the First Call consensus estimate of 20 cents in earnings per diluted share. Accordingly, 1999 sales are expected to be in the $62 million to $63 million range and the net loss for 1999 would be about $3.3 million to $4.1 million, or 20 cents to 25 cents per share. biz.yahoo.com